Kardium has announced results from a pivotal trial for its Globe PFA system, with some outlets describing the one-year results as "impressive". The company has also received additional funding, reportedly $250M, to advance its PFA technology. The trial results and financing announcement come as Kardium works to develop its treatment for atrial fibrillation, with other companies, such as Abbott, also making progress in the field of pulsed field ablation systems.